Q3 2024 Gilead Sciences Inc Earnings Call Transcript
Key Points
- Gilead Sciences Inc (GILD) reported a strong quarter with a 9% growth in HIV sales year-over-year, driven by higher demand and pricing.
- The company increased its 2024 guidance across multiple metrics, including revenue, non-GAAP gross margin, operating income, and EPS.
- Lenacapavir received breakthrough therapy designation from the FDA, with plans to file for approval by the end of the year, highlighting its potential impact on HIV prevention.
- Livdelzi, a new therapy for primary biliary cholangitis, exceeded internal expectations in its initial launch, indicating strong market demand.
- Gilead Sciences Inc (GILD) demonstrated robust growth in its oncology segment, particularly with Trodelvy, which saw a 17% year-over-year increase in sales.
- The company faced competitive headwinds in its cell therapy segment, impacting sales and expected to continue into 2025.
- Gilead Sciences Inc (GILD) recorded a $1.8 billion impairment charge related to the IPR&D assets acquired from Immunomedics, affecting GAAP financial results.
- Sequentially, liver disease sales declined 12% due to inventory dynamics and fewer patient starts in HCV.
- The company is discontinuing development of Trodelvy in second line plus metastatic non-small cell lung cancer due to regulatory feedback.
- Despite strong overall performance, non-GAAP diluted EPS decreased to $2.02 per share from $2.29 per share in the same period last year, primarily due to higher acquired IPR&D and tax expenses.
Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be your host for today in a moment. (Operator Instructions)
I'll now hand the call over to Jacquie Ross, Vice President of Investor Relations and Corporate Strategic Finance.
Thank you, Rebecca. Just after market closed today, we issued a press release with earnings results for the third quarter of 2024. The press release, slides, and supplementary data are available on the investors section of our website at gilead.com.
The speakers on todayâs call will be our Chairman and Chief Executive Officer, Daniel OâDay; our Chief Commercial Officer, Johanna Mercier; our Chief Medical Officer, Merdad Parsey; and our Chief Financial Officer, Andrew Dickinson. After that, weâll open the call to Q&A, where the team will be joined by Cindy Perettie, the Executive Vice President of Kite.
Before we get started, let me
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
